

[NEPTUNE](#) is a Phase 3 pediatric clinical trial evaluating OV101 to determine if this investigational medicine changes the severity of symptoms in people with Angelman syndrome, such as the ability to sleep, use of gross and fine motor skills, behavior and communication.

Recently, members of the Angelman community have reached out asking a few questions about the NEPTUNE study. Thanks for being in contact!

Below are answers to those questions:

How do we sign up?

- Visit www.ANGELMANstudy.com and take the study pre-screener.
- If your child qualifies, you will be prompted to select from a list of clinical trial sites. You will receive an email response connecting you to a study coordinator who will schedule an appointment.
- NEPTUNE clinical trial sites are opening on a rolling basis. Some sites are already active and can schedule patients immediately. All sites will be active soon, but if you are willing to travel and would rather schedule a visit immediately, you can contact one of our active clinical trial sites.
- If you don't receive an immediate response, it may be that the study site you requested is not active yet but should be active soon. Thanks for your patience. Please contact us if you don't receive the information you need.

If we take part in this trial will it eliminate us from other trials?

- During participation in [NEPTUNE](#), an individual cannot take another investigational medicine of any kind. After successful completion of NEPTUNE, participants have the option of enrolling in [ELARA, an Open Label Extension Study](#).
- Participation in the NEPTUNE study lasts approximately 4 months.
- After completion of NEPTUNE, participation in studies involving investigational treatments other than OV101 should be considered with consultation from your physician.
- Remember, when considering any clinical trial, the decision should be made in consultation with your physician. To find out more information on clinical trials visit www.clinicaltrials.gov.

Where can we get more info?

- Information on how to enroll in the NEPTUNE study can be found by visiting www.ANGELMANstudy.com, emailing AngelmanStudy@ovidrx.com or by contacting the designated call center open 8am-8pm EDT Monday through Friday: (855) 235-3138.